Theres another pill to help people lose weight After years of study and lots of questions from the Food and Drug Administration questions a pill called Contrave finally got the   Thursday Its the third diet medicine to get the regulatory goahead in recent years But the other drugs  Qsymia and Belviq    Many insurers have been   Contrave for better or worse is a combination of two drugs that have been around for a long time One is   an antidepressant sold as Wellbutrin thats also been used to help people stop smoking The other is   a medicine thats prescribed to help people stay off drugs and alcohol Contrave is intended for people who are obese or who are overweight and have other weightrelated health problems such as high blood pressure and type  diabetes In a study of people without diabetes  percent of patients who got Contrave lost at least  percent of their weight over about a year compared with  percent for those who took a placebo A study in people with diabetes found that  percent received Contrave lost at least  percent of their weight compared with  percent who got a placebo You can find the study details in the   who might consider prescribing the drug People in the studies also reduced the calories they consumed and exercised In one study the patients also got counseling about weight loss Contrave is supposed to be used in combination with other weightloss approaches Contrave has side effects The most common ones include nausea constipation and headache About a quarter of people taking the drugs in clinical tests stopped taking the drug because of side effects Contrave also comes with a stern warning about the potential for suicidal thoughts and behavior which is consistent with the   All told almost half of people taking Contrave or the placebo used for comparison stopped taking their pills before the studies were finished The FDA says people who havent lost at least  percent of their weight after taking Contrave for  weeks should stop the medicine because its unlikely to help them Back in  the FDA   despite a recommendation for approval from an outside panel of experts The agency was concerned among other things about potential heart risks Orexigen Therapeutics developer of the drug agreed to run a study looking at cardiovascular risks The interim results apparently were reassuring enough for the FDA to approve Contrave But the company hasnt released the data Orexigen and Takeda agreed to conduct a new study looking at heart risks as a condition for approval of the drug Contrave will be available in pharmacies this fall according to Takeda Pharmaceuticals and Orexigen the companies working on the drugs marketing How much will it cost The companies wont say yet For price its not Takedas policy to disclose spokesman Bob Skinner told me in an email He said Takeda will offer a savings program to make the medicine more affordable for people whose insurance wont cover the medicine Insurance coverage has been a sore spot for obesity drugs Theres very little value perceived in antiobesity care Dr Jeffrey I Mechanick immediate past president of the American Association of Clinical Endocrinologists tells Shots A   found that many insurers said they dont cover obesity interventions because theyve not been asked to do so Still he said another drug is a good thing because it gives patients and doctors another option for care